Abstract:Background Nonalcoholic fatty liver disease (NAFLD), also known as metabolic associated fatty liver disease (MAFLD), is a common liver condition characterized by excessive fat accumulation in the liver which is not caused by alcohol. The main causes of NAFLD are obesity and insulin resistance. Dachaihu decoction (DCHD), a classic formula in traditional Chinese medicine, has been proved to treat NAFLD by targeting different aspects of pathogenesis and is being progressively used in the treatment of NAFLD. DCHD is commonly applied in a modified form to treat the NAFLD. In light of this, it is imperative to conduct a systematic review and meta-analysis to assess the effectiveness and safety of DCHD in the management of NAFLD. There is a need for a systematic review and meta-analysis to assess the effectiveness and safety of modified DCHD in treating NAFLD. Objective The objective of this meta-analysis was to systematically assess the clinical effectiveness and safety of DCHD in treating NAFLD. Methods This meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Including seven databases, both Chinese and English databases were searched for relevant studies. The quality of included studies was carefully assessed using the bias risk assessment tool in the Cochrane Handbook. Eligible articles were the source of extracted data which was meta-analyzed by using Review Manager 5.4 and Stata 17.0. Results A total of 10 studies containing 825 patients were included. Compared with conventional treatments, combined treatment could clearly improve the liver function of NAFLD patients, which could reduce the levels of ALT (MD = −7.69 U/L, 95% CI: −11.88 to −3.51, p < 0.001), AST (MD = −9.58 U/L, 95% CI: −12.84 to −6.33, p < 0.01), and it also had a certain impact on regulating lipid metabolism, which could reduce the levels of TC (MD = −0.85 mmol/L, 95% CI: −1.22 to 0.48, p < 0.01), TG (MD = −0.45 mmol/L, 95% CI: −0.64 to 0.21, p < 0.01). Adverse event showed that DCHD was relatively safe. Due to the inclusion of less than 10 trials in each group, it was not possible to conduct a thorough analysis of publication bias. Conclusion According to the meta-analysis, in the treatment of the NAFLD, it is clear that the combination of DCHD was advantages over conventional treatment alone in improving liver function, regulating lipid metabolism. Additionally, DCHD demonstrates a relatively safe profile. Nevertheless, due to limitations in the quality and quantity of the studies incorporated, the effectiveness and safety of DCHD remain inconclusive. Consequently, further high-quality research is imperative to furnish more substantial evidence supporting the widespread clinical application of DCHD. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023397353 , CRD42023397353.

Clinical Research of Modified Ling-Gui-zhu-gan Decoction Combined with Short-Term Very-Low-calorie-diet in Treatment of Hyperlipidemia Combined with Fatty Liver(splenic Hypofunction and Dampness Accumulation Type)

Study on clinical effect of Yiqi Yangyin and Huoxue Prescription imposed on fatty liver in type 2 diabetes mellitus

Clinical Observation on 46 Cases of Type 2 Diabetes Mellitus Complicated with Fatty Liver Treated by Yiqi Yangyin and Huoxue Herbal Medicines

Effect of Xuezhikang Combined with Silibinin on Serum Lipids of Fatty Liver Patients

Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial

The Clinical Observation on Ganlanjiangzhi Capsule for 80 Patients with Hyperlipidemia Fatty Liver

Clinical study of diabetes combined with non-alcoholic fatty liver disease with soothing liver for dredging collaterals formula

Danggui Baizhu Decoction Treated Alcoholic Fatly Liver in Singapore and Malaysia

Effect Evaluation of Community Grading Management of Dyslipidemia in Hangzhou

Clinical Observation of "qinggan Huayu Decoction" in Treating Hepatic Fibrosis Following Nonalcoholic Fatty Liver Diseases

"Tongfu Huayu Decoction" for the treatment of nonalcoholic fatty liver disease: report of 120 cases

Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics

Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota

Clinical Observation of Treating Dyslipidemia Accumulation of Phlegm Stasis with Danggui Shaoyao San

Clinical Evidence and Potential Mechanisms of Complementary Treatment of Ling Gui Zhu Gan Formula for the Management of Serum Lipids and Obesity

Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease

Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway

The efficacy and safety of Dachaihu decoction in the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis

Clinical Study on "fufang Yuqin Capsule" in Treating Simple Nonalcoholic Fatty Liver Disease

Yinchen Linggui Zhugan Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Modulation of SIRT1/Nrf2 Signaling Pathway and Gut Microbiota.

Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats